A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 13, 2023

Primary Completion Date

February 20, 2024

Study Completion Date

March 12, 2024

Conditions

Hyper-low-density Lipoprotein (LDL) Cholesterolemia

Interventions

DRUG

180mg of ETC-1002(bempedoic acid)

180mg, tablet, once daily, for 12 weeks

DRUG

Placebo

placebo, tablet, once daily, for 12 weeks

Trial Locations (1)

Rinku General Medical Center, Izumisano